Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03908437 · ClinicalTrials.gov registry record · Phase 4
Rapid Initiation of Drug Treatment Engagement
A Phase 4 study of Opioid Use Disorder and Overdose, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 104
- Enrollment target
- 1
- Study location
NCT03908437: Completed Phase 4 study of Opioid Use Disorder and Overdose, sponsored by University of Pennsylvania.
NCT03908437 is a Phase 4 study of Opioid Use Disorder and Overdose that has completed, run by University of Pennsylvania. The registered enrollment target is 104 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03908437, a Phase 4 study of Opioid Use Disorder and Overdose, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed research will evaluate the ability of a mobile, rapid induction procedure to engage individuals in ongoing medication assisted treatment. A total of 250 untreated individuals meeting criteria for opioid use disorder and at high risk of opioid overdose will be enrolled in the study. Recruitment will take place in two targeted neighborhoods of Philadelphia (Kensington and South Philadelphia) with a high prevalence of fatal and non-fatal opioid overdose. A total of 250 participants will be engaged in the research. Following informed consent and determination of eligibility, 125 individuals will be enrolled as they engage with the mobile, rapid induction team and 125 individuals will be enrolled as they seek treatment from the CRC Episcopal Hospital (serving Kensington area) or BAC/CRC Hall Mercer Community Mental Health (serving South Philadelphia). The intervention group will receive four weeks of treatment with buprenorphine /naloxone and support for treatment engagement provided by a case manager and a peer recovery specialist. All participants will be assessed at baseline and then 1- and 6-month following enrollment. The primary endpoint for the study is continued enrollment in medication-assisted treatment at 6-month post-enrollment. The proposed research will evaluate the ability of a mobile, rapid induction procedure to engage individuals in ongoing medication assisted treatment. The specific aims are: * Aim 1: To evaluate the impact of the mobile, transitional MAT intervention on its ability to engage participants in targeted, existing MAT treatment slots at 1- and 6-month post-enrollment. * Aim 2: To evaluate the impact of the mobile intervention on subsequent drug use and overdoses at 6-month post-enrollment. * Aim 3: To assess the acceptability and costs of the intervention. The program and patient costs of delivering and participating in the intervention will be documented.
Primary Outcome
Number of participants receiving treatment with medication for opioid use disorder at 1-month post-enrollment
Conditions Studied
Interventions
- DRUG buprenorphine/naloxone
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 4 |
What the finished NCT03908437 record still lists
NCT03908437 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which buprenorphine/naloxone is the first listed.
NCT03908437 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03908437 about?
NCT03908437 is a clinical study titled "Rapid Initiation of Drug Treatment Engagement". The proposed research will evaluate the ability of a mobile, rapid induction procedure to engage individuals in ongoing medication assisted treatment. A total of 250 untreated individuals meeting criteria for opioid use disorder and at high risk of opioid overdose will be enrolled in the study. Recr...
What is the current status of trial NCT03908437?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 104 participants. The study started on 2019-07-15. Estimated completion is 2023-06-30.
What conditions does trial NCT03908437 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Overdose.
What interventions are being tested in trial NCT03908437?
The interventions under investigation include: buprenorphine/naloxone (DRUG).
Who is sponsoring clinical trial NCT03908437?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03908437 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03908437's enrollment target sits among peer trials
104 127th of 257 higher than 130 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
RECRUITING · Phase 4
-
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
RECRUITING · Phase 4
-
Assessing Optimal XRB Initiation Points in Jail
RECRUITING · Phase 4
-
Low-dose Buprenorphine Initiation for Opioid Use Disorder
RECRUITING · Phase 4
-
Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.
RECRUITING · Phase 4
-
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI